| 词条 | Vaborbactam |
| 释义 |
| drug_name = | INN = | type = | IUPAC_name = {(3R,6S)-2-Hydroxy-3-[2-(thiophen-2-yl)acetamido]- 1,2-oxaborinan-6-yl}acetic acid | image = Vaborbactam.svg | width = 250 | alt = | caption = | pronounce = | tradename = | Drugs.com = | MedlinePlus = | licence_EU = | licence_US = | DailyMedID = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_US_comment = | pregnancy_category = | dependency_liability = | addiction_liability = | routes_of_administration = IV | legal_AU = | legal_AU_comment = | legal_CA = | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = | legal_UK_comment = | legal_US = | legal_US_comment = | legal_UN = | legal_UN_comment = | legal_status = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 1360457-46-0 | CAS_supplemental = | class = | ATCvet = | ATC_prefix = None | ATC_suffix = | ATC_supplemental = | PubChem = 56649692 | PubChemSubstance = | IUPHAR_ligand = | DrugBank = | ChemSpiderID = 35035409 | UNII = 1C75676F8V | KEGG = D10998 | ChEBI = | ChEMBL = | NIAID_ChemDB = | synonyms = | chemical_formula = | C = 12 | H = 16 | B = 1 | N = 1 | O = 5 | S = 1 | charge = | molecular_weight = | SMILES = B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)CC2=CC=CS2)O | Jmol = | StdInChI = 1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1 | StdInChI_comment = | StdInChIKey = IOOWNWLVCOUUEX-WPRPVWTQSA-N | density = | density_notes = | melting_point = | melting_high = | melting_notes = | boiling_point = | boiling_notes = | solubility = | specific_rotation = | sec_combustion = }}Vaborbactam (INN)[1] is a non-β-lactam β-lactamase inhibitor discovered by Rempex Pharmaceuticals, a subsidiary of The Medicines Company. While not effective as an antibiotic by itself, it restores potency to existing antibiotics by inhibiting the beta-lactamase enzymes that would otherwise degrade them. When combined with an appropriate antibiotic it can be used for the treatment of gram-negative bacterial infections.[2] In the United States, the combination drug meropenem/vaborbactam (Vabomere) is approved by the Food and Drug Administration for complicated urinary tract infections and pyelonephritis.[3] BiochemistryVaborbactam is a boronic acid, β-lactamase inhibitor with a high affinity for serine β-lactamases, including Klebsiella pneumoniae carbapenemase (KPC).[4] Vaborbactam inhibits a variety of β-lactamases, exhibiting a 69 nM Ki against the KPC-2 carbapenemase and even lower inhibition constants against CTX-M-15 and SHV-12. Boronic acids are unusual in their ability to reversibly form covalent bonds with alcohols such as the active site serine in a serine carbapenemase. This property enables them to function as transition state analogs of serine carbapenemase-catalyzed lactam hydrolysis and thereby inhibit these enzymes.[2] Carbapenemases can be broadly divided into two different categories based on the mechanism they use to hydrolyze the lactam ring in their substrates: Metallo-β-lactamases contain bound zinc ions in their active sites and are therefore inhibited by chelating agents like EDTA, while serine carbapenemases feature an active site serine that participates in the hydrolysis of the substrate.[5] Serine carbapenemase-catalyzed hydrolysis employs a three-step mechanism featuring acylation and deacylation steps analogous to the mechanism of protease-catalyzed peptide hydrolysis, proceeding through a tetrahedral transition state.[5][6] Given their mechanism of action, the possibility of off-target effects brought about through inhibition of endogenous serine hydrolases is an obvious possible concern in the development of boronic acid β-lactamase inhibitors, and in fact boronic acids like bortezomib have previously been investigated or developed as inhibitors of various human proteases.[2] Vaborbactam, however, is a highly specific β-lactamase inhibitor, with an IC50 >> 1 mM against all human serine hydrolases against which it has been tested.[2] Consistent with its high in vitro specificity, vaborbactam exhibited a good safety profile in human phase I clinical trials, with similar adverse events observed in both placebo and treatment groups.[7] Hecker et al. argue this specificity results from the higher affinity of human proteases to linear molecules; thus it is expected that a boron heterocycle will have zero effect on them. References1. ^{{cite web | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 75 | url = http://apps.who.int/medicinedocs/documents/s22359en/s22359en.pdf | publisher = World Health Organization | pages = 161–2}} {{Cell wall disruptive antibiotics}}2. ^1 2 3 {{cite journal | last1 = Hecker | first1 = SJ | last2 = Reddy | first2 = KR | last3 = Totrov | first3 = M | last4 = Hirst | first4 = GC | last5 = Lomovskaya | first5 = O | last6 = Griffith | first6 = DC | last7 = King | first7 = P | last8 = Tsivkovski | first8 = R | last9 = Sun | first9 = D | last10 = Sabet | first10 = M | last11 = Tarazi | first11 = Z | last12 = Clifton | first12 = MC | last13 = Atkins | first13 = K | last14 = Raymond | first14 = A | last15 = Potts | first15 = KT | last16 = Abendroth | first16 = J | last17 = Boyer | first17 = SH | last18 = Loutit | first18 = JS | last19 = Morgan | first19 = EE | last20 = Durso | first20 = S | last21 = Dudley | first21 = MN | title = Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases | journal = Journal of Medicinal Chemistry | date = 14 May 2015 | volume = 58 | issue = 9 | pages = 3682–92 | doi = 10.1021/acs.jmedchem.5b00127 | pmid = 25782055 | issn = 0022-2623}} 3. ^{{Cite press release | url = https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573955.htm | title = FDA approves new antibacterial drug | publisher = Food and Drug Administration | date = August 29, 2017}} 4. ^Burgos RM, Biagi MJ, Rodvold KA, Danziger LH. Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection. Expert Opin Drug Metab Toxicol. 2018 Oct;14(10):1007-1021. {{PMID|30106599}} {{doi|10.1080/17425255.2018}} 5. ^1 {{cite journal | last1 = Queenan | first1 = AM | last2 = Bush | first2 = K | title = Carbapenemases: the Versatile β-Lactamases | journal = Clinical Microbiology Reviews | date = 13 July 2007 | volume = 20 | issue = 3 | pages = 440–58 | doi = 10.1128/CMR.00001-07 | pmid = 17630334 | issn = 0893-8512 | pmc = 1932750}} 6. ^{{cite journal|last1=Lamotte-Brasseur | first1 = J | last2 = Knox | first2 = J | last3 = Kelly | first3 = JA | last4 = Charlier | first4 = P | last5 = Fonzé | first5 = E | last6 = Dideberg | first6 = O | last7 = Frère | first7 = JM | title = The Structures and Catalytic Mechanisms of Active-Site Serine β-Lactamases | journal = Biotechnology and Genetic Engineering Reviews | date = December 1994 | volume = 12 | issue = 1 | pages = 189–230 | doi = 10.1080/02648725.1994.10647912 | pmid = 7727028 | issn = 0264-8725}} 7. ^{{cite journal | last1 = Griffith | first1 = DC | last2 = Loutit | first2 = JS | last3 = Morgan | first3 = EE | last4 = Durso | first4 = S | last5 = Dudley | first5 = MN | title = Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects | journal = Antimicrobial Agents and Chemotherapy | date = October 2016 | volume = 60 | issue = 10 | pages = 6326–32 | doi = 10.1128/AAC.00568-16 | pmid = 27527080 | issn = 0066-4804 | pmc = 5038296}} 6 : Carboxamides|Antibiotics|Beta-lactamase inhibitors|Carboxylic acids|Thiophenes|Organoboron compounds |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。